Full text is available at the source.
Abstract
Adherence and persistence to GLP-1 receptor agonist anti-obesity medications among Mississippi Medicaid members following coverage initiation in July 2023 is not well understood.
- Real-world adherence patterns to GLP-1 receptor agonists may vary significantly within Medicaid populations.
- Understanding adherence and persistence is crucial after the resolution of medication shortages.
- The study focuses on Mississippi Medicaid members, providing regional insights into the use of anti-obesity medications.
Simplified